drugset
drugset / Trial / NCT06637020

Phase Ib Clinical Study of HDM1005 Injection

NCT06637020 ↗

Phase 1 Completed 40 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HDM1005 injection in overweight or obese subjects.

Timeline

Start
2024-06-20
Primary completion
2024-12-27
Completion
2025-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM1005 Unknown 0.5 mg Subcutaneous
Subject HDM1005 Unknown 1 mg Subcutaneous
Subject HDM1005 Unknown 2 mg Subcutaneous
Subject HDM1005 Unknown 4 mg Subcutaneous
Subject HDM1005 Unknown 8 mg Subcutaneous

Indications

morbid obesity